CagriSema: What the Research Shows About the Next Weight Loss Drug

CagriSema, a once-weekly injection that combines a GLP-1 receptor agonist with a novel amylin analogue, achieved 22.7% average body weight loss in Phase 3 trials - the highest efficacy recorded for a single obesity injection to date.

*This article is for informational purposes only and does not constitute medical advice. CagriSema is not yet FDA-approved and is not available at Prescriva. Consult your healthcare provider about your treatment options.*

---

If you have been following the news around obesity medicine lately, you have probably heard the name CagriSema. The Phase 3 results generated headlines because they showed something that has not been seen before in a single injectable: weight loss approaching what bariatric surgery produces, without the operating room.

This article explains what CagriSema actually is, how the science works, what the clinical trials found, and what it means for people who are managing their weight right now.

---

What Is CagriSema?

CagriSema is a fixed-dose combination drug developed by Novo Nordisk. Each weekly injection contains two active compounds:

• Cagrilintide 2.4 mg - a long-acting analogue of amylin, a hormone your pancreas naturally releases at mealtimes
• Semaglutide 2.4 mg - a GLP-1 receptor agonist (the same active ingredient in Wegovy and Ozempic, at the same dose as Wegovy)

Novo Nordisk filed a New Drug Application (NDA) with the FDA in December 2025. As of June 2026, the FDA is conducting its standard review. A decision is expected in approximately Q4 2026.

CagriSema is not currently approved anywhere in the world and is not available at Prescriva or any other telehealth provider.

What makes the drug scientifically interesting is not simply that it combines two compounds - it is that those two compounds target hunger through separate, complementary pathways. That distinction matters, and it is worth understanding.

---

How the Two Mechanisms Work Together

What GLP-1 Medications Do

If you have read about semaglutide or tirzepatide, you are already familiar with GLP-1 receptor agonists. GLP-1 is a hormone released in the gut after eating. It signals the hypothalamus - the brain's appetite-regulation center - to reduce hunger. It also slows gastric emptying, helping you feel full longer, and it stimulates insulin release while suppressing glucagon.

The result is a significant reduction in caloric intake, driven by lower appetite and slower digestion.

What Amylin Does (and Why It Matters)

Amylin (technically called islet amyloid polypeptide, or IAPP) is a hormone released by the same pancreatic beta cells that release insulin - but its job is different. Amylin signals the brainstem (specifically the area postrema) and hypothalamus to:

• Reduce meal size by promoting earlier satiety during eating
• Slow gastric emptying from a separate pathway than GLP-1
• Suppress glucagon after meals
• Regulate blood glucose post-meal

Research published in the International Journal of Molecular Sciences describes amylin as a "neuroendocrine hormone that provides complementary satiety signals to GLP-1 from a distinct receptor pathway" [1]. People with obesity tend to have impaired amylin signaling - a gap that GLP-1 drugs alone do not address.

Cagrilintide is a long-acting analogue of amylin designed to activate this separate pathway continuously, once weekly.

Why Combining Them Produces More Than the Sum of Parts

Think of it this way: semaglutide turns down the "hunger volume" in your brain. Cagrilintide independently turns down the "portion size dial" via a different signal. When both pathways are activated simultaneously, they address hunger from two complementary directions.

In the REDEFINE trials, participants on CagriSema lost significantly more weight than participants on either compound alone - a finding that suggests genuine synergy between the two mechanisms rather than simple addition.

---

What the Clinical Trials Show

REDEFINE 1: Obesity Without Type 2 Diabetes

This was the pivotal Phase 3 trial in adults with obesity or overweight plus at least one weight-related health condition, but without type 2 diabetes. The study enrolled 3,417 participants and ran for 68 weeks.

Key results for the CagriSema group [2]:

• 22.7% mean body weight loss at 68 weeks, versus 2.3% with placebo
• For comparison: semaglutide alone produced 16.1% weight loss, cagrilintide alone produced 11.8%
• 60% of CagriSema participants lost 20% or more of their body weight
• 23% of participants lost 30% or more - approaching surgical outcomes
• Significant reductions in blood pressure, LDL cholesterol, and C-reactive protein (a marker of inflammation) [5]
• Discontinuation rate due to side effects: 6 to 8.4% - comparable to semaglutide monotherapy

REDEFINE 2: Obesity with Type 2 Diabetes

Type 2 diabetes creates additional challenges for weight loss medications because elevated blood sugar and insulin resistance both affect how the body responds to treatment. The REDEFINE 2 trial enrolled adults with both obesity and T2D [3]:

• 15.7% average weight loss at 68 weeks, versus 3.1% with placebo
• HbA1c reduction of 1.91 percentage points - meaningfully better than semaglutide alone
• 89.7% of CagriSema participants achieved 5% or more body weight loss, versus 30.3% with placebo
• Significant improvements in fasting glucose and insulin sensitivity

REDEFINE 4: Head-to-Head Against Tirzepatide

This comparison generated particular attention because tirzepatide (Zepbound) is currently the most effective approved weight loss medication available. At 84 weeks, CagriSema produced 23% average weight loss [4].

The honest read of the data: CagriSema did not meet the pre-specified non-inferiority threshold against tirzepatide 15 mg (the highest available dose). Tirzepatide maintained a small edge at maximum dose.

That said, context matters. CagriSema still outperforms any standalone GLP-1 by a substantial margin. The two medications work through different mechanisms, and the small gap between them at maximum doses does not diminish how meaningful CagriSema's efficacy is in absolute terms. It also raises the possibility that different patients may respond differently to GLP-1/GIP versus GLP-1/amylin combinations - a question ongoing research will clarify.

---

Safety Profile

The most common side effects in the REDEFINE trials were gastrointestinal:

• Nausea, vomiting, diarrhea, and constipation - consistent with the GLP-1 drug class
• These effects are typically mild to moderate and concentrated during the dose-escalation phase (when the medication is being gradually increased)
• The GI side effect profile is similar to semaglutide monotherapy - no new or unexpected signals were seen

Discontinuation due to GI side effects was low (6 to 8.4% in REDEFINE 1), suggesting that most patients tolerated the medication with appropriate titration support.

One important note: long-term cardiovascular outcome data is not yet available for CagriSema. For context, the SELECT trial (PMID 37952131) demonstrated cardiovascular risk reduction with semaglutide in high-risk patients over a median 34 months [6]. A comparable study for CagriSema has not yet been conducted.

---

How CagriSema Compares

---

When Will CagriSema Be Available?

The FDA's standard review timeline for a New Drug Application is approximately 10 to 12 months. With the NDA filed in December 2025, a decision is projected for approximately Q4 2026.

A few practical considerations:

Brand name: Novo Nordisk has not announced a commercial brand name for CagriSema as of June 2026.

Cost: No pricing has been disclosed. Based on comparable launches (Wegovy launched at approximately $1,300/month; Zepbound at approximately $1,000/month before coupons), branded CagriSema will likely carry a similar or higher list price before insurance and manufacturer savings programs.

Compounded versions: Unlike semaglutide, which has been compoundable because of FDA shortage list status, there is currently no pathway for 503A or 503B pharmacies to compound cagrilintide. Amylin analogues are not on the FDA shortage list, and the complex fixed-ratio formulation makes compounding unlikely even after approval.

For most patients who want evidence-based, medically supervised weight loss access today, compounded semaglutide remains the most accessible and affordable option.

---

Frequently Asked Questions

What is CagriSema and how is it different from semaglutide?

CagriSema combines semaglutide (a GLP-1 receptor agonist) with cagrilintide (an amylin analogue). Semaglutide on its own acts on GLP-1 receptors to reduce appetite and slow gastric emptying. CagriSema adds a second mechanism - amylin receptor activation - that addresses meal size and satiety through a separate brain pathway. The result is greater weight loss than either compound produces alone.

How much weight can people lose on CagriSema?

In the REDEFINE 1 Phase 3 trial (3,417 adults, 68 weeks), participants taking CagriSema lost an average of 22.7% of body weight. Sixty percent lost 20% or more, and 23% lost 30% or more. Individual results vary based on adherence, lifestyle factors, and metabolic profile.

When will CagriSema receive FDA approval?

Novo Nordisk filed the NDA in December 2025. Based on standard FDA review timelines, an approval decision is expected in approximately Q4 2026. This is a projection, not a guarantee.

Can I get CagriSema now, or through Prescriva?

No. CagriSema is not FDA-approved and is not available anywhere, including Prescriva, as of June 2026. There is no current legal pathway to obtain or compound cagrilintide.

Is CagriSema better than tirzepatide?

CagriSema and tirzepatide achieved similar weight loss results in Phase 3 trials (22.7% vs. approximately 22.5% in pivotal trials). In a head-to-head comparison (REDEFINE 4), CagriSema did not meet non-inferiority against tirzepatide 15 mg, meaning tirzepatide maintained a small advantage at maximum doses. Both substantially outperform standalone GLP-1 medications. Neither is yet available as a compounded option from telehealth providers.

---

What This Means for Your Weight Loss Journey Today

CagriSema represents a genuine scientific advance. The combination of GLP-1 and amylin pathways addresses appetite through two complementary mechanisms, and the REDEFINE trials produced the strongest efficacy data ever seen in a single obesity injection. For patients and providers watching the pipeline, this is an important development.

The practical reality: FDA approval is expected in Q4 2026. Brand-name pricing will likely be comparable to Wegovy and Zepbound. Compounding is not expected to be a pathway.

For patients who want to start medically supervised weight loss treatment now - rather than waiting 6 to 12 months for a possible approval - compounded semaglutide from Prescriva is an evidence-based, physician-prescribed option available today.

Ready to explore your options? [Check your eligibility](/assessment) and connect with a Prescriva provider to discuss whether a GLP-1 program is right for you.

---

Sources

1. Eržen S, et al. Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity. *Int J Mol Sci.* 2024 Jan 26. PMID: [38338796](https://pubmed.ncbi.nlm.nih.gov/38338796/)

1. Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2025 Aug 14. PMID: [40544433](https://pubmed.ncbi.nlm.nih.gov/40544433/)

1. Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. *N Engl J Med.* 2025 Aug 14. PMID: [40544432](https://pubmed.ncbi.nlm.nih.gov/40544432/)

1. Yamauchi T, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone. *Lancet Diabetes Endocrinol.* 2026 Jun. PMID: [42009015](https://pubmed.ncbi.nlm.nih.gov/42009015/)

1. Verma S, et al. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. *Hypertension.* 2026 Feb. PMID: [41328546](https://pubmed.ncbi.nlm.nih.gov/41328546/)

1. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med.* 2023 Dec 14. PMID: [37952131](https://pubmed.ncbi.nlm.nih.gov/37952131/)

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021 Mar 18. PMID: [33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med.* 2022 Jul 21. PMID: [35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)

---

*This article is for informational and educational purposes only. It does not constitute medical advice. CagriSema is an investigational drug that is not FDA-approved and is not available through Prescriva or any other healthcare provider. Prescriva offers compounded semaglutide, which is not FDA-approved and is not the same as or equivalent to Wegovy or Ozempic. Individual results vary. Consult your healthcare provider before starting, stopping, or changing any medical treatment.*